SMMT NASDAQ
Summit Therapeutics Inc.
1W: +7.4%
1M: +14.8%
3M: +5.2%
YTD: -4.3%
1Y: -18.2%
3Y: +772.9%
5Y: +221.1%
$16.75
+0.07 (+0.39%)
Weekly Expected Move ±7.4%
$14
$16
$17
$18
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-12-06
Earliest Filing
2025-10-22
Latest Filing
investor: 4
partner: 4
Counterparties (Filed by SMMT)
8 relationshipsCompanies named in SMMT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Akeso, Inc. | — | investor | Participated as an investor in Summit Therapeutics Inc.'s private placement of common stock. | 2025-10-22 | View |
| 667, L.P. | — | investor | Investor in private placement of common stock | 2024-06-03 | View |
| Baker Brothers Life Sciences, L.P. | — | investor | Investor in private placement of common stock | 2024-06-03 | View |
| Baker Bros. Advisors, L.P. | — | investor | Affiliated investor in private placement | 2024-06-03 | View |
| Akeso, Inc. | — | partner | Counterparty to License Agreement amendment for ivonescimab collaboration | 2024-06-03 | View |
| Akeso, Inc. | — | partner | Collaboration and License Agreement for oncology assets with upfront cash payment and stock issuance | 2023-01-20 | View |
| Akeso Biopharma Co., Ltd. | — | partner | Original counterparty to the License Agreement prior to amendment | 2023-01-20 | View |
| Akeso, Inc. | — | partner | Collaboration and License Agreement for in-licensing ivonescimab (SMT112) in US, Canada, Europe, and Japan. | 2022-12-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Material Agreement; Unregistered Equity Sales; Bylaws Amendment; Other Events; Exhibits | Agreement | View |
| 2026-09-15 | Other Events; Exhibits | View | |
| 2026-09-14 | Other Events; Exhibits | View | |
| 2026-09-03 | Other Events; Exhibits | View | |
| 2026-08-26 | Other Events; Exhibits | View | |
| 2026-08-05 | Other Events; Exhibits | View | |
| 2026-07-23 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-23 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-22 | Other Events; Exhibits | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-06-11 | Regulation FD | View | |
| 2026-06-03 | Other Events | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-02-23 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-29 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-22 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-10-20 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR